Fractionated stereotactic radiotherapy in residual or recurrent nasopharyngeal carcinoma

Dhanachai, Mantana; P, Kraiphibul; Dangprasert, Somjai; Puataweepong, Putipun; Narkwong, Ladawan; Laothamatas, Jiraporn; Kulapraditharom, Boonchu; Sirachainan, Ekaphop; Yongvithisatid, Pornpan

doi:10.1080/02841860601103050

Cited by 18 publications

(12 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Chua et al [35] treated 48 local failure NPC patients using SRS with a median dose of 12.5 Gy, and the 5-year LFFS and OS rate were 47.2% and 46.9%, respectively. Dhanachai et al [21] treated 32 patients with residual or recurrent NPC using FSRT at a total dose of 17 to 59.4 Gy (4 to 25 fractions), the 3-year local progression-free rate and OS rate were 37.9% and 71.2%, respectively. Chen et al [36] treated 64 patients with FSRT of 12–15 Gy, and the 3-year LC and OS rate were 93.1% and 84.9%, respectively.…”

Section: Discussionmentioning

confidence: 99%

“…Dhanachai et al [21] reported significantly worse LC in patients receiving chemotherapy, but the author stated that it was not possible to conclude that chemotherapy led to the poor LC because there were selection factors which could lead to the worse outcome. In our study, tumor volume was not a significant independent predictor.…”

Section: Discussionmentioning

confidence: 99%

“…Chua et al [22] reported significant association between tumor volume and LC or survival. Wu et al [20] reported that tumor volume was a significant predictor of progression-free survival (PFS) and distant metastasis-free survival (DMFS) but not LFFS, While Dhanachai et al [21] reported that chemotherapy was the only significant factor for local PFS.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Fractionated stereotactic radiotherapy for 136 patients with locally residual nasopharyngeal carcinoma

Liu

Jianping

et al. 2013

Radiat Oncol

View full text Add to dashboard Cite

BackgroundTo evaluate the efficacy and toxicity of fractionated stereotactic radiotherapy (FSRT) in patients with residual nasopharyngeal carcinoma (NPC).MethodsFrom January 2000 to December 2009, 136 NPC patients with residual lesions after primary radiotherapy (RT) were treated by FSRT. The total dose of primary RT was 68.0-78.0 Gy (median, 70.0 Gy). The median time from the primary RT to FSRT was 24.5 days. Tumor volumes for FSRT ranged from 0.60 to 77.13 cm3 (median, 13.45 cm3). The total FSRT doses were 8.0-32.0Gy (median, 19.5 Gy) with 2.0-10.0 Gy per fraction.ResultsFive-year local failure-free survival (LFFS), freedom from distant metastasis (FFDM), overall survival (OS), and disease free survival (DFS) rates for all patients were 92.5%, 77.0%, 76.2%, and 73.6%, respectively. No statistical significant differences were found in LFFS, DFS and OS in patients with stage I/II versus stage III/ IV diseases. Nineteen patients exhibited late toxicity. T stage at diagnosis was a significant prognostic factor for OS and DFS. Age was a prognostic factor for OS.ConclusionFSRT after external beam radiotherapy provides excellent local control for patients with residual NPC. The incidence of severe late toxicity is low and acceptable. Further investigation of optimal fractionation regimens will facilitate reduction of long-term complications.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Fractionated stereotactic radiotherapy for 136 patients with locally residual nasopharyngeal carcinoma

Liu

Jianping

et al. 2013

Radiat Oncol

View full text Add to dashboard Cite

show abstract

“…[9] 32 rezidüel veya tekrarlayan nazofarenks kanserli hastayı LINAC bazlı fraksiyone stereotaktik radyocerrahi (FSRT) kullanarak tedavi etmişler-dir. Hastaların histolojisi 2'si WHO tip 1, 15'i WHO tip 2, 14'ü WHO tip 3 idi ve 1 hastanın histolojisi bilinmiyordu.…”

Section: Discussionunclassified

Stereotactic radiotherapy in locally recurrent nasopharyngeal cancer

Mayadağlı¹,

Ekici²,

Ozseker³

et al. 2011

J Kartal TR

View full text Add to dashboard Cite

ÖzetAmaç: Bu çalışmamızda amacımız, kliniğimize başvuran nüks nazofarenks hastalarında uygulanan ikinci seri stereotaktik radyoterapi sonuçlarını değerlendirmektir. Hastalar ve Yöntem:Ağustos 2009 ile Mart 2011 yılları arasında kliniğimize başvuran ve CyberKnife cihazı ile tedavi edilen 12 hastanın bulguları retrospektif olarak değerlen-dirildi. Hastaların hepsi öncesinde küratif dozda radyoterapi alan, sonrasında nazofarenks bölgesinde lokal olarak nüks eden hastalardı. Bulgular:Ortalama sağkalım 57 ay ve 6 yıllık ortalama sağ-kalım %34 idi. Nüks sonrası 2 yıllık ortalama sağkalım ise %37 idi.Sonuç: Bizim deneyimlerimize göre nüks eden nazofarenks kanserlerinde stereotaktik radyoterapi palyasyonda etkin bir tedavi yöntemi ve lokal kontrolde iyi bir seçenektir.

show abstract

“…Stereotactic radiation can be used for T1-2 or small T3 recurrences. Both single dose of 8-20 Gy [42,43] and fractionation of 14-65 Gy [44,45,46 ] have been used. Three-year local control rate of 31-100% has been reported.…”

Section: External Beam Re-irradiationmentioning

confidence: 99%

Recurrent nasopharyngeal carcinoma: surgical salvage vs. additional chemoradiation

Wei

Kwong²

2011

Current Opinion in Otolaryngology &Amp; Head &Amp; Neck Surgery

View full text Add to dashboard Cite

show abstract

Fractionated stereotactic radiotherapy in residual or recurrent nasopharyngeal carcinoma

Cited by 18 publications

References 18 publications

Fractionated stereotactic radiotherapy for 136 patients with locally residual nasopharyngeal carcinoma

Fractionated stereotactic radiotherapy for 136 patients with locally residual nasopharyngeal carcinoma

Stereotactic radiotherapy in locally recurrent nasopharyngeal cancer

Recurrent nasopharyngeal carcinoma: surgical salvage vs. additional chemoradiation

Contact Info

Product

Resources

About